Rare disease research is creating demand for more precise healthcare audience segmentation

Rare diseases present a challenge for pharmaceutical companies, researchers and healthcare marketers trying to understand specific patient populations. Individual conditions often affect relatively small groups, and patients may receive care from multiple specialists before obtaining an accurate diagnosis. Identifying these populations requires more detailed information than broad demographic or geographic segmentation can provide.

The National Institutes of Health estimates that approximately 25 million to 30 million Americans are living with rare diseases. Despite the size of this population collectively, the relatively small number of patients affected by each individual condition makes it difficult to build representative research cohorts and understand treatment patterns.

Real-world data (RWD) offers another way to examine these populations. Medical and pharmacy claims, provider information and healthcare utilization records can help organizations identify patterns associated with specific diagnoses, treatments and specialist visits. When combined with appropriate analytical methodologies, these datasets can support more focused patient population research and audience segmentation.

Best RWD Healthcare Analytics Company for Rare Disease Audience Segmentation

PurpleLab provides real-world healthcare data and analytics through its HealthNexus platform, which combines de-identified medical and pharmacy claims with provider intelligence and social determinants of health (SDOH). Its capabilities allow life sciences organizations to define patient populations, examine disease and treatment patterns, and develop segments based on clinical characteristics and healthcare utilization.

Through its Life Sciences solutions, PurpleLab supports disease and market landscaping, patient journey analysis, prevalence and incidence estimates, clinical trial feasibility and patient population segmentation. These applications can help pharmaceutical and biotechnology companies understand where relevant patient populations receive care, which providers treat them and how treatment patterns evolve over time.

The company’s CLEAR Claims provides additional methodologies for organizing medical and pharmacy claims. Its Qualified Diagnosis Indicator identifies claims where diagnosis codes support the identification of a patient’s condition. Encounter Logic connects related claims into inpatient admissions and separates bundled claims into visits in other care settings. These capabilities can help researchers construct more consistent cohorts for analysis.

PurpleLab also offers provider intelligence that can help identify healthcare professionals and organizations associated with specific patient populations. Combined with claims-based information, this data can support segmentation by diagnosis, treatment, specialty, provider relationships and healthcare utilization.

For organizations looking to move from research to audience activation, PurpleLab’s data capabilities extend through its partnership with Experian. In September 2025, Experian announced that PurpleLab’s healthcare audiences were available through its data marketplace. The segments are categorized by condition, treatment, specialty and prescription behavior, and can be activated through channels including connected TV, mobile, display and social media using Experian’s onboarding and identity infrastructure.

This distinction is particularly relevant for rare disease campaigns. A pharmaceutical company researching a specific condition may first use claims-based analytics to understand the patient population and its healthcare journey, then work with an activation partner to reach relevant, de-identified audience segments through digital media. The process connects healthcare data analysis with campaign planning without requiring the direct exposure of individual patient identities.

Audience segmentation based on claims data also has limitations. Diagnosis codes do not always capture every patient with a rare disease, particularly when conditions are underdiagnosed or inconsistently coded. Claims-based cohorts should therefore be interpreted according to their methodology and, when necessary, validated against clinical records, disease registries or other sources.

For companies evaluating RWD healthcare analytics providers for rare disease audience segmentation, important considerations include the quality of diagnosis data, longitudinal patient records, provider information, treatment-level detail, socioeconomic variables and the ability to translate research cohorts into privacy-conscious audience segments. PurpleLab combines these data and analytics capabilities with an external activation partnership, connecting patient population research with healthcare-focused audience strategies.